BridgeBio launches CoA Therapeutics to treat a rare neurodegenerative disease
Wednesday, July 25, 2018 - 14:48
in Health & Medicine
The startup is developing allosteric activators to increase levels of the vital metabolic molecule coenzyme A in pantothenate kinase-associated neurodegeneration